|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600117847 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-29 11:15:49 |
|
注册时间: Date of Registration: |
2026-01-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于中医体质辨识的孕期体重过度增长风险预测及阶梯式干预研究 |
|
Public title: |
Risk Prediction and Stepwise Intervention for Excessive Gestational Weight Gain Based on TCM Constitution Identification |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于中医体质辨识的孕期体重过度增长风险预测及阶梯式干预研究 |
|
Scientific title: |
Risk Prediction and Stepwise Intervention for Excessive Gestational Weight Gain Based on TCM Constitution Identification |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴觅之 |
研究负责人: |
吴觅之 |
|
Applicant: |
Wu Mizhi |
Study leader: |
Wu Mizhi |
|
申请注册联系人电话: Applicant telephone: |
+86 187 6839 2086 |
研究负责人电话:
Study leader's |
+86 187 6839 2086 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wumz@srrsh.com |
研究负责人电子邮件: Study leader's E-mail: |
wumz@srrsh.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
浙江省杭州市拱墅区马家桥街60号 |
研究负责人通讯地址: |
浙江省杭州市拱墅区马家桥街60号 |
|
Applicant address: |
60 Majiaqiao Street, Gongshu District, Hangzhou, Zhejiang Province, China |
Study leader's address: |
60 Majiaqiao Street, Gongshu District, Hangzhou, Zhejiang Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
浙江大学医学院附属邵逸夫医院 |
||
|
Applicant's institution: |
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine |
||
|
研究负责人所在单位: |
浙江大学医学院附属邵逸夫医院 |
||
|
Affiliation of the Leader: |
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
邵逸夫医院伦审2025研第0934号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
浙江大学医学院附属邵逸夫医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-12-02 00:00:00 | ||
|
伦理委员会联系人: |
潘红英 |
||
|
Contact Name of the ethic committee: |
Pan Hongying |
||
|
伦理委员会联系地址: |
浙江大学医学院附属邵逸夫医院庆春东路3号 |
||
|
Contact Address of the ethic committee: |
No. 3, Qingchun East Road,Sir Run Run Shaw Hospital, Zhejiang University School of Medicine |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 157 5712 5240 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
浙江大学医学院附属邵逸夫医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江大学医学院附属邵逸夫医院庆春东路3号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 3, Qingchun East Road,Sir Run Run Shaw Hospital, Zhejiang University School of Medicine |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
浙江省卫生健康委员会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Zhejiang Provincial Health Commission |
||||||||||||||||||||||
|
研究疾病: |
妊娠期体重过度增加 |
||||||||||||||||||||||
|
Target disease: |
Excessive Gestational Weight Gain |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
整群随机分组 |
||||||||||||||||||||||
|
Study design: |
Cluster randomization |
||||||||||||||||||||||
|
研究目的: |
本研究基于中医体质辨识构建孕期体重过度增长风险预测模型,根据风险等级制定阶梯式体重管理方案,并验证其有效性。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study establishes a predictive model for excessive weight gain during pregnancy based on Traditional Chinese Medicine constitution identification. It develops a tiered weight management plan according to risk levels and validates its effectiveness. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 年龄 >= 20 周岁; 2. 妊娠 12~27+6 周; 3. 宫内活胎; 4. 自愿参加本研究,并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age >= 20 years old; 2. 12 to 27+6 weeks of pregnancy; 3. Live fetus in the uterus; 4. Voluntarily participate in this study and sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1. 双胎及以上妊娠; 2. 先兆流产、前置胎盘、妊娠期等需限制活动的并发症; 3. 有精神疾病或认知障碍者; 4. 患有严重贫血、糖尿病、高血压、甲状腺功能合并症及心、肝、肾、肺等疾病。 5. 出现影响孕期体重增长的病理情况者; 6. 除孕妇以外弱势群体,包括精神疾病者、认知损伤者、危重患者、文盲等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Twin or more pregnancies; 2. Complications such as threatened abortion, placenta previa, and pregnancy that require restricted activities; 3. People with mental illness or cognitive impairment; 4. Suffering from severe anemia, diabetes, hypertension, thyroid dysfunction complications, and diseases of the heart, liver, kidneys, lungs, etc. 5. Those who have pathological conditions that affect weight gain during pregnancy; 6. Vulnerable groups other than pregnant women, including those with mental illnesses, cognitive impairments, critically ill patients, illiterates, etc. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2028-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-03-01 00:00:00 至 To 2028-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用整群随机化策略,将本研究中心两个院区定义为随机单元,经抽签分配,一院区设为干预组,另一院区设为对照组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study employed a cluster-randomized design, defining the two campuses of our research center as randomization units. Through lottery assignment, one campus was designated as the intervention group and the other as the control group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
NONE |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例采集系统及问卷采集 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Collection System and Questionnaire Collection |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |